Trial Profile
Prospective, randomized, open-label, clinical trial comparing the effects of dapagliflozin and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Sitagliptin (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 May 2020 Status changed from recruiting to active, no longer recruiting.
- 28 May 2018 New trial record